Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE2
70 participants
INTERVENTIONAL
2025-03-06
2032-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy and Safety of Anlotinib, Irinotecan and Temozolomide in the Treatment of Refractory or Recurrent Neuroblastoma in Children: an Open, Single Arm, Single Center, Phase II Clinical Study
NCT04842526
Study of Tumor Samples From Patients With Ependymoma Treated on the Children's Oncology Group ACNS0121 Trial
NCT01407744
Combination Chemotherapy Followed by Second-Look Surgery and Radiation Therapy in Treating Children With Nonmetastatic Medulloblastoma or Primitive Neuroectodermal Tumor
NCT00006461
PNOC 001: Phase II Study of Everolimus for Recurrent or Progressive Low-grade Gliomas in Children
NCT01734512
Temsirolimus, Irinotecan Hydrochloride, and Temozolomide in Treating Younger Patients With Relapsed or Refractory Solid Tumors
NCT01141244
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
SECONDARY OBJECTIVES I. To determine the two-year progression-free survival (PFS) and overall survival (OS) of participants with newly diagnosed, gross-totally resected, non-metastatic ETMR (Cohort 1).
II. To determine the two-year progression-free survival (PFS) and overall survival (OS) of participants with newly diagnosed, gross-totally resected, non-metastatic ETMR (Cohort 2).
III. To determine the two-year progression-free survival (PFS), overall survival (OS) and objective response rate of participants with newly diagnosed, incompletely resected and/or metastatic ETMR (Cohort 3A and 3B)
EXPLORATORY OBJECTIVES:
I. To validate the utility of a liquid miRNA biomarker in blood and Cerebral spinal fluid (CSF) as a correlative marker of a participant's disease status.
II. To better define the genomic landscape of ETMR.
OUTLINE:
Participants with newly diagnosed ETMR will obtain either gross total, or sub-total resection surgery prior to enrollment. After surgery, participants will be assigned to 1 of 4 possible cohorts:
Cohorts 1 and 2: Participants with newly diagnosed, gross-totally resected, non-metastatic ETMR.
Cohorts 3A and 3B: Participants with newly diagnosed, incompletely resected and/or metastatic ETMR.
Participants will be assessed for survival outcomes for up to 2 years. Follow-up procedures are to be captured under the PNOC COMP protocol. Participants will be followed under the Pediatric Neuro-Oncology Consortium (PNOC) COMP protocol until death or withdrawal from study.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cohort 1: Gross-total resection, non-metastatic, early radiotherapy
Participants will undergo gross total resection of the tumor prior to enrollment into this cohort. Standard dose induction chemotherapy and 6-weeks of early focal radiotherapy, followed by and a second standard dose induction chemotherapy for a total of 12 weeks of chemotherapy; 18 weeks of treatments in all. Participants will be followed for up to 2 years.
Non-Investigational Surgical Resection
Undergo surgery directly before study enrollment as part of planned care.
Temozolomide
Participants assigned to or whom receive optional RT will receive concurrent temozolomide
Tumor Tissue Sample
Tumor tissue will be collected for correlative studies
Blood Sample
Blood samples will be collected for correlative studies
Cerebrospinal Fluid (CSF) Sample
CSF samples will be collected for correlative studies
Radiotherapy (RT)
Undergo RT
Chemotherapy Drug, Cancer - Physician's Choice
One or more of the following may be assigned by the physician (physician's choice) per standard of care guidelines upon study enrollment following surgery: Cytarabine, Carboplatin, Cisplatin, Vincristine Sulfate injection (Vincristine PFS), Topotecan Hydrochloride, Dactinomycin, Thiotepa, Filgrastim, Cyclophosphamide, or Doxorubicin Hydrochloride. Not all participants will receive all possible drug regimens.
Cohort 2: Gross-total resection, non-metastatic, high-dose chemotherapy
Participants will undergo gross total resection of the tumor prior to enrollment into this cohort. Participants will receive 6 weeks of induction chemotherapy and 3 cycles (approximately 4 weeks each) of high-dose chemotherapy with stem cell rescue and will have the option to receive radiotherapy at the completion of therapy, for a total of 18-24 weeks. Participants will be followed for up to 2 years.
Non-Investigational Surgical Resection
Undergo surgery directly before study enrollment as part of planned care.
Temozolomide
Participants assigned to or whom receive optional RT will receive concurrent temozolomide
Tumor Tissue Sample
Tumor tissue will be collected for correlative studies
Blood Sample
Blood samples will be collected for correlative studies
Cerebrospinal Fluid (CSF) Sample
CSF samples will be collected for correlative studies
Radiotherapy (RT)
Undergo RT
Chemotherapy Drug, Cancer - Physician's Choice
One or more of the following may be assigned by the physician (physician's choice) per standard of care guidelines upon study enrollment following surgery: Cytarabine, Carboplatin, Cisplatin, Vincristine Sulfate injection (Vincristine PFS), Topotecan Hydrochloride, Dactinomycin, Thiotepa, Filgrastim, Cyclophosphamide, or Doxorubicin Hydrochloride. Not all participants will receive all possible drug regimens.
Cohort 3A: Metastatic or residual disease, early radiotherapy
Participants metastatic disease or residual disease following their initial surgical interventions prior to enrollment into this cohort will receive standard dose induction chemotherapy and 6-weeks of early focal radiotherapy, followed by and a second standard dose induction chemotherapy for a total of 12 weeks of chemotherapy; 18 weeks of treatments in all. Participants will be followed for up to 5 years.
Non-Investigational Surgical Resection
Undergo surgery directly before study enrollment as part of planned care.
Temozolomide
Participants assigned to or whom receive optional RT will receive concurrent temozolomide
Tumor Tissue Sample
Tumor tissue will be collected for correlative studies
Blood Sample
Blood samples will be collected for correlative studies
Cerebrospinal Fluid (CSF) Sample
CSF samples will be collected for correlative studies
Radiotherapy (RT)
Undergo RT
Chemotherapy Drug, Cancer - Physician's Choice
One or more of the following may be assigned by the physician (physician's choice) per standard of care guidelines upon study enrollment following surgery: Cytarabine, Carboplatin, Cisplatin, Vincristine Sulfate injection (Vincristine PFS), Topotecan Hydrochloride, Dactinomycin, Thiotepa, Filgrastim, Cyclophosphamide, or Doxorubicin Hydrochloride. Not all participants will receive all possible drug regimens.
Cohort 3B: Metastatic or residual disease, high-dose chemotherapy
Participants metastatic disease or residual disease following their initial surgical interventions prior to enrollment into this cohort. Participants will receive 6 weeks of induction chemotherapy and 3 cycles (approximately 4 weeks each) of high-dose chemotherapy with stem cell rescue and will have the option to receive radiotherapy at the completion of therapy, for a total of 18-24 weeks. Participants will be followed for up to 5 years.
Non-Investigational Surgical Resection
Undergo surgery directly before study enrollment as part of planned care.
Temozolomide
Participants assigned to or whom receive optional RT will receive concurrent temozolomide
Tumor Tissue Sample
Tumor tissue will be collected for correlative studies
Blood Sample
Blood samples will be collected for correlative studies
Cerebrospinal Fluid (CSF) Sample
CSF samples will be collected for correlative studies
Radiotherapy (RT)
Undergo RT
Chemotherapy Drug, Cancer - Physician's Choice
One or more of the following may be assigned by the physician (physician's choice) per standard of care guidelines upon study enrollment following surgery: Cytarabine, Carboplatin, Cisplatin, Vincristine Sulfate injection (Vincristine PFS), Topotecan Hydrochloride, Dactinomycin, Thiotepa, Filgrastim, Cyclophosphamide, or Doxorubicin Hydrochloride. Not all participants will receive all possible drug regimens.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Non-Investigational Surgical Resection
Undergo surgery directly before study enrollment as part of planned care.
Temozolomide
Participants assigned to or whom receive optional RT will receive concurrent temozolomide
Tumor Tissue Sample
Tumor tissue will be collected for correlative studies
Blood Sample
Blood samples will be collected for correlative studies
Cerebrospinal Fluid (CSF) Sample
CSF samples will be collected for correlative studies
Radiotherapy (RT)
Undergo RT
Chemotherapy Drug, Cancer - Physician's Choice
One or more of the following may be assigned by the physician (physician's choice) per standard of care guidelines upon study enrollment following surgery: Cytarabine, Carboplatin, Cisplatin, Vincristine Sulfate injection (Vincristine PFS), Topotecan Hydrochloride, Dactinomycin, Thiotepa, Filgrastim, Cyclophosphamide, or Doxorubicin Hydrochloride. Not all participants will receive all possible drug regimens.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. For enrollment, a confirmation of a minimum of 10-20 unstained formalin-fixed paraffin-embedded (FFPE) slides or 1 block (15-20 mg) with tumor content of 40% or greater is required. Anything less must be discussed and approved by the study chairs prior to enrollment.
3. Prior Therapy:
1. Cohort 1 participants must not have received any prior tumor-directed therapy other than surgical resection.
2. Cohort 2 and 3 participants may receive tumor-directed therapy prior to enrollment. These participants must be discussed with study chairs prior to enrollment.
4. Participants must not have received prior radiation for treatment of tumor.
5. Participants of any age are eligible.
6. Participants should begin induction chemotherapy within 28 days of the most recent definitive surgical procedure. Participants beginning therapy beyond 28 days from surgery, will need to discuss with study chairs.
7. Cohort specific eligibility
1. Cohort 1: Gross-total resection, Eligible for early radiotherapy (please see age criteria below), and no evidence of metastatic disease.
2. Cohort 2: Gross-total resection, high dose chemotherapy (please see age criteria below), and no evidence of metastatic disease.
3. Cohort 3A: Metastatic or residual disease, and early radiotherapy.
4. Cohort 3B: Metastatic or residual disease, and high dose chemotherapy.
5. Radiotherapy Age Criteria (at the time of planned radiation): \>12 months of age for participants with infratentorial tumor OR \>15 months of age for participants with supratentorial tumor. For participants being treated on radiotherapy-containing arms, the legal parent/guardian or patient and the physician must be willing to allow the use of radiotherapy for treatment.
8. Performance Score: Karnofsky \>= 50 for participants \> 16 years of age and Lansky \>= 50 for participants \<=16 years of age. Participants who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score.
9. Organ Function Requirements:
1. Peripheral absolute neutrophil count (ANC) \> 75,000/mm3
2. Platelet count \> 75,000/mm3 (transfusion independent, defined as not receiving platelet transfusions for at least 72 hours prior to enrollment).
10. Adequate Renal Function defined as:
a. Serum creatinine \< 1.5 x upper limit normal (ULN) based on age and gender.
11. Adequate Liver Function defined as:
1. Total bilirubin \< 1.5 x upper limit of normal (ULN) for age; in presence of Gilbert's syndrome, total bilirubin \< 3 x ULN or direct bilirubin \< 1.5 x ULN,
2. alanine aminotransferase (ALT) \< 3 x ULN,
3. aspartate aminotransferase (AST) \< 3 x ULN,
12. Adequate Neurologic Function defined as:
a. Participants with seizure disorder may be enrolled if well controlled. Participants on enzyme inducing anticonvulsants may be excluded pending interaction(s) with study drugs.
13. As chemotherapeutic agents used in this trial are known to be teratogenic, women and men of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation and 4 months after completion of study therapy. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.
14. Participants must be enrolled on PNOC COMP prior to enrollment on PNOC031 if PNOC COMP is open to accrual at the enrolling institution.
15. A legal parent/guardian or patient must be able to understand, and willing to sign, a written informed consent and assent document, as appropriate.
Exclusion Criteria
2. Participants who are receiving any other tumor directed investigational agents.
3. History of allergic reactions attributed to compounds of similar chemical or biologic composition to the agents used in study.
4. Uncontrolled intercurrent illness.
5. Women of childbearing potential must not be pregnant or breast-feeding.
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pediatric Neuro-Oncology Consortium
OTHER
Solving Kids' Cancer
OTHER
University of California, San Francisco
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Sabine Mueller, MD, PhD, MAS
Role: PRINCIPAL_INVESTIGATOR
University of California, San Francisco
Derek Hanson, MD
Role: STUDY_CHAIR
Hackensack Meridian Health
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Alabama at Birmingham
Birmingham, Alabama, United States
University of California, San Francisco
San Francisco, California, United States
Johns Hopkins University
Baltimore, Maryland, United States
Washington University in St. Louis
St Louis, Missouri, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Role: backup
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NCI-2025-01764
Identifier Type: REGISTRY
Identifier Source: secondary_id
240830
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.